Stockreport

Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference [Yahoo! Finance]

Aura Biosciences, Inc.  (AURA) 
PDF Special Protocol Assessment (SPA) , with time to tumor progression as the primary endpoint and top-line data targeted for Q4 2027 (enrollment expected to finish in The [Read more]